175 related articles for article (PubMed ID: 35064101)
1. RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80.
Tian Q; Gao H; Zhou Y; Zhu L; Yang J; Wang B; Liu P; Yang J
Cell Death Dis; 2022 Jan; 13(1):71. PubMed ID: 35064101
[TBL] [Abstract][Full Text] [Related]
2. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells.
Wells CD; Fawcett JP; Traweger A; Yamanaka Y; Goudreault M; Elder K; Kulkarni S; Gish G; Virag C; Lim C; Colwill K; Starostine A; Metalnikov P; Pawson T
Cell; 2006 May; 125(3):535-48. PubMed ID: 16678097
[TBL] [Abstract][Full Text] [Related]
3. Angiomotin-p130 inhibits β-catenin stability by competing with Axin for binding to tankyrase in breast cancer.
Yang J; Zhang X; Chen Z; Shen Y; Wang F; Wang Y; Liu Y; Liu P; Yang J
Cell Death Dis; 2019 Feb; 10(3):179. PubMed ID: 30792381
[TBL] [Abstract][Full Text] [Related]
4. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
5. Angiomotin promotes breast cancer cell proliferation and invasion.
Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J
Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626
[TBL] [Abstract][Full Text] [Related]
6. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.
Yi C; Troutman S; Fera D; Stemmer-Rachamimov A; Avila JL; Christian N; Persson NL; Shimono A; Speicher DW; Marmorstein R; Holmgren L; Kissil JL
Cancer Cell; 2011 Apr; 19(4):527-40. PubMed ID: 21481793
[TBL] [Abstract][Full Text] [Related]
7. Rho differentially regulates the Hippo pathway by modulating the interaction between Amot and Nf2 in the blastocyst.
Shi X; Yin Z; Ling B; Wang L; Liu C; Ruan X; Zhang W; Chen L
Development; 2017 Nov; 144(21):3957-3967. PubMed ID: 28947533
[TBL] [Abstract][Full Text] [Related]
8. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
10. AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin.
Couderc C; Boin A; Fuhrmann L; Vincent-Salomon A; Mandati V; Kieffer Y; Mechta-Grigoriou F; Del Maestro L; Chavrier P; Vallerand D; Brito I; Dubois T; De Koning L; Bouvard D; Louvard D; Gautreau A; Lallemand D
Neoplasia; 2016 Jan; 18(1):10-24. PubMed ID: 26806348
[TBL] [Abstract][Full Text] [Related]
11. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.
Moleirinho S; Hoxha S; Mandati V; Curtale G; Troutman S; Ehmer U; Kissil JL
Elife; 2017 May; 6():. PubMed ID: 28464980
[TBL] [Abstract][Full Text] [Related]
12. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos.
Hirate Y; Hirahara S; Inoue K; Suzuki A; Alarcon VB; Akimoto K; Hirai T; Hara T; Adachi M; Chida K; Ohno S; Marikawa Y; Nakao K; Shimono A; Sasaki H
Curr Biol; 2013 Jul; 23(13):1181-94. PubMed ID: 23791731
[TBL] [Abstract][Full Text] [Related]
13. VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP β2-chimaerin.
Elaimy AL; Guru S; Chang C; Ou J; Amante JJ; Zhu LJ; Goel HL; Mercurio AM
Sci Signal; 2018 May; 11(528):. PubMed ID: 29717062
[TBL] [Abstract][Full Text] [Related]
14. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
[TBL] [Abstract][Full Text] [Related]
15. [Research progress of Merlin protein and its signal pathway in tumor].
Zhu YJ; Shan CG
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 May; 30(9):757-762. PubMed ID: 29771032
[TBL] [Abstract][Full Text] [Related]
16. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.
Basu-Roy U; Bayin NS; Rattanakorn K; Han E; Placantonakis DG; Mansukhani A; Basilico C
Nat Commun; 2015 Apr; 6():6411. PubMed ID: 25832504
[TBL] [Abstract][Full Text] [Related]
17. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
18. The role of Motin family proteins in tumorigenesis-an update.
Amirifar P; Kissil J
Oncogene; 2023 Apr; 42(16):1265-1271. PubMed ID: 36973516
[TBL] [Abstract][Full Text] [Related]
19. Rich1 negatively regulates the epithelial cell cycle, proliferation and adhesion by CDC42/RAC1-PAK1-Erk1/2 pathway.
Zhang J; Wang J; Zhou YF; Ren XY; Lin MM; Zhang QQ; Wang YH; Li X
Cell Signal; 2015 Sep; 27(9):1703-12. PubMed ID: 26004135
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer.
Mota MSV; Jackson WP; Bailey SK; Vayalil P; Landar A; Rostas JW; Mulekar MS; Samant RS; Shevde LA
Carcinogenesis; 2018 Sep; 39(9):1165-1175. PubMed ID: 29893810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
